Gazi Medical Journal · Published 2025-10-13 · DOI 10.12996/gmj.2024.4074
Anaplastic lymphoma kinase (ALK) rearrangement is detected at a low rate in non-small cell lung cancer (NSCLC). Patients with ALK rearrangements have poor responses to conventional cytotoxic chemotherapy. Brigatinib is one of the ALK-tyrosine kinase inhibitors recommended for first-line treatment in metastatic NSCLC. Local ablative therapies are applied in the treatment of oligometastatic disease in NSCLC. In this case, a patient with lung adenocarcinoma with ALK-rearranged isolated adrenal metastasis was treated with adjuvant brigatinib after sequential surgery. A 23-month disease-free survival was obtained. The case reported here represents the use of adjuvant therapy with ALK inhibitors in ALK-positive oligometastatic NSCLC in eligible patients.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →